Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre-Reference-Cited by-同舟云学术

Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre

Published:2021-05-27 Issue:3 Volume:62 Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Australas J Dermatol

Author:

Gallo Giuseppe¹^ORCID,Rostagno Elisabetta¹,Siliquini Niccolò¹,Stroppiana Elena¹,Verrone Anna¹,Ortoncelli Michela¹,Quaglino Pietro¹,Dapavo Paolo¹,Ribero Simone¹^ORCID

Affiliation:

1. Department of Medical Sciences Section of Dermatology University of Turin Turin Italy

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.13632

Reference6 articles.

1. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

2. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis

5. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching between Originators and Biosimilars in Dermatology: A Systematic Review of Real-World Clinical Studies;Biologics;2023-04-27

2. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis;Journal of Dermatological Treatment;2023-01-19

3. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?;Dermatologic Therapy;2022-09-14